Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05656833
Other study ID # SterlingIRB Study #9727
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 28, 2022
Est. completion date July 2023

Study information

Verified date December 2022
Source UnionDerm
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of our study is to determine the efficacy of combined topical cysteamine cream with a 1927 diode non-ablative laser (Clear + Brilliant Permea®; Solta Medical, Inc.), compared to topical cysteamine (Cyspera) alone in the treatment of melasma. The main questions it aims to answer are - If melasma treatment with topical cysteamine cream is more effective when used with the Clear & Brilliant® Permea laser - The safety & efficacy of melasma treatment in various skin types using the Clear & Brilliantt® Permea laser in combination with topical cysteamine. Participants will - Come into our office for an initial screening appointment to determine if participant is eligible for the study - Come in for 3 laser treatments, 4 weeks apart, on 1 side of the face - Use the study provided Cyspera topical cream every day on the entire face for the 12 weeks on the study. Researchers will compare the side of the participants face not treated with laser to the side of the face treated with laser. The participants will be using Cyspera on both sides of their face.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date July 2023
Est. primary completion date April 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 74 Years
Eligibility Inclusion Criteria: - Healthy subjects of Skin Type I-VI females. - Subjects must be between 18 and 74 years of age, and must have visible melasma on the face. - Subjects must read, understand, and sign the Informed Consent. - Subjects must be willing and able to comply with all follow-up requirements. Exclusion Criteria: - Subjects must not have active or localized or systemic infections. - Subjects must not be immunocompromised. - Subjects must not have a coagulation disorder, and must not be using anticoagulation -medications. - Subjects must not have history of surgical or cosmetic treatment, including prior skin lightening agents, microneedling or microdermabrasion, or laser or light-based therapies, to the planned treatment areas in the prior 8 weeks. - Subjects must not have photosensitivity or allergy. - Subjects must not be mentally incompetent. - Subjects must not be pregnant or breastfeeding. - History of skin cancer or pre-cancerous lesions in the treatment area - Subjects must not be currently using aspirin or antioxidants. - Subjects must not refuse to sign the Informed Consent document and/or refuse to comply with all follow-up requirements. - Subjects must never have had gold therapy. - Subjects must never have had radiation therapy to the face. Recent or current suntan or sunburn within 2 weeks. - Clinically dysplastic nevi in the treatment area. - Subjects must not have had collagen, other methods of tissue augmentation, botox, chemical peels, dermabrasion, or resurfacing within the last year. - Oral retinoid (Accutane or Soriatane) or photosensitizing drugs, e.g. Declomycin®, a tetracycline with light absorption in the range of 400 to 450 nm use within 24 months of study entry. - Topical retinoid therapy on face within one month of study entry. - History of keloids or hypertrophic scars - A history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins, or photodermatosis.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Fractional 1927nm Low-Powered Diode Laser
Clear & Brilliant Permea® Laser used on the side of the face randomized to receive laser
Other:
Topical Cysteamine
Topical Cysteamine cream will be used on the entire face.

Locations

Country Name City State
United States UnionDerm New York New York

Sponsors (4)

Lead Sponsor Collaborator
UnionDerm Scientis, Skin of Color Society, Solta Medical

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary objective of our study is to determine the efficacy of combined topical cysteamine cream with a 1927 diode non-ablative laser (Clear + Brilliant Permea®; Solta Medical, Inc.), compared to topical cysteamine alone in the treatment of melasma. Photographic assessment by two blinded dermatologists will measure changes will assess improvement in melasma by modified Melasma Area and Involvement Index (mMASI). Total mMASI score ranges from 0 - 24, with a higher score indicating more involvement and/or severity of melasma 12 Weeks
See also
  Status Clinical Trial Phase
Completed NCT05013801 - A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma N/A
Recruiting NCT06174545 - Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma N/A
Completed NCT01695356 - Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma Phase 4
Recruiting NCT06278948 - Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma N/A
Not yet recruiting NCT05911698 - Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma. N/A
Recruiting NCT04597203 - Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial N/A
Completed NCT02138539 - Evaluation of an Herbal-Based De-Pigmenting System Phase 4
Recruiting NCT01661556 - Clinical Trial of Hydroquinone Versus Miconazol in Melasma Phase 4
Completed NCT01001624 - Melanil in the Treatment of Melasma Phase 3
Terminated NCT03415685 - Lutronic PicoPlus Exploratory Clinical Trial N/A
Recruiting NCT04765930 - Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma N/A
Completed NCT04137263 - Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging N/A
Recruiting NCT03686787 - Oral Tranexamic Acid and Laser for Treatment of Melasma Phase 4
Completed NCT05969587 - Cysteamine Compared to Hydroquinone in Melasma Phase 3
Completed NCT00472966 - Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma Phase 4
Completed NCT00500162 - Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma Phase 4
Completed NCT05884151 - Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma Phase 1
Completed NCT05887219 - Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma Phase 1
Recruiting NCT03308370 - Platelet Rich Plasma in Treatment of Melasma Phase 3
Not yet recruiting NCT05099601 - Silymarin Cream Versus Combined Silymarin Cream and Microneedling in Treatment of Melasma Phase 4